Clinical Impact of HOME Oxygen SATURation Measurement (SATURHOME)
Study Details
Study Description
Brief Summary
The use of saturometry at home is more and more widespread in patients suffering from interstitial pulmonary diseases (IPD), the patients seeing it as reassurance and a concrete way to follow the evolution of their disease. However, there are no studies evaluating the real clinical benefit of taking saturation at home in this population. In addition, clinical experience seems rather to demonstrate an increase in the anxiety level and the number of clinically unnecessary consultations related to the use of this measure.
The secondary objectives are to determine the impact of this measurement on: (1) the health care use (telephone calls, medical consultations and hospitalizations), (2) dyspnea score, (3) the anxiety and depression score (HADS score) and (4) the physical activity level. The exploratory objectives will be to determine if the measurement of saturation at home makes it possible to (1) predict the occurrence of acute exacerbations of fibrosis, (2) effectively predict the decline in respiratory function tests and (3) 1-year mortality. The investigator will also assess whether this measure makes it possible to screen patients with oxygen therapy needs at home. The investigator hypothesize that measuring oxygen saturation at home will lead to a significant deterioration in quality of life, an increase in the use of health care, a significant increase in the rate of anxiety and depression, dyspnea and a decrease in the physical activity level.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Measurement tools
-
Quality of life: King's Brief Interstitial Lung Disease
-
Anxiety and depression score: HADS score
-
Dyspnea score : UCSD questionnaire
-
Physical activity level during 7 days: MoveMonitor by McRoberts
-
Home base saturation: Nonin Ny vantagr 9590
-
Disease evolution : complete lung function (plethymography, sprimoetry, DLCO), 6-minute walking test (following the ATS recommandation)
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Intervention Group Intervention group participants will be asked to measure their oxygen saturation on a daily basis. |
Other: Saturation at home
Clinical benefit of taking saturation at home in interstitial lung disease
|
| No Intervention: Control Group Usual Care |
Outcome Measures
Primary Outcome Measures
- Quality of life by questionnaire [1 year]
Impact of home base saturometry on quality of life
Secondary Outcome Measures
- Health care use (phone calls, medical consultation) [1 year]
Impact of home base saturometry on health car use as number and principal reason for : telephone calls, medical consultations and hospitalizations.
- Dyspnea score [1 year]
Impact of home base saturometry on dyspnea score with the University of California, San Diego Shortness of breath Questionnaire (UCSD) in a scale between 0 to 120 where 120 is the worst score.
- Anxiety and depression score [1 year]
Impact of home base saturometry on anxiety and depression score with the Hospital Anxiety and Depression Scale Questionnaire (HADs) in a scale between 0 to 42, where 42 is the worst score.
- Physical activity level [1 year]
Impact of home base saturometry on physical activity level measure by accelerometer (McRoberts) and define by steps number.
- Energy expenditure [1 year]
Impact of home base saturometry on energy expenditure (number of kilocalories burn by day), measure by accelerometer (McRoberts).
Other Outcome Measures
- Acute exacerbation [1 year]
Impact of home base saturometry on predict the occurrence of acute exacerbations of fibrosis. Occurence: number of exacerbation of fibrosis during the year.
- Pulmonary function decline [1 year]
Impact of home base saturometry on predict the decline in respiratory function tests, principally the forced vital capacity.
- Mortality [1 year]
Impact of home base saturometry on 1-year mortality prediction
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Fibrosing interstitial lung disease
-
Saturation below 90% during the 6-minute walk test
-
Clinically stable
Exclusion Criteria:
- Oxygen dependent at rest
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec | Québec | Canada | G1V 4G5 |
Sponsors and Collaborators
- Laval University
- Fondation IUCPQ
Investigators
- Principal Investigator: Geneviève Dion, MD, Institut universitaire de pneumologie et cardiologue de Québec - ULaval
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2021-3417